Bank of New York Mellon’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Bank of New York Mellon’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-14,886	Closed	-$1K	–	4388
2016 Q3	$1K	Hold	14,886	–	–	﹤0.01%	4265
2016 Q2	$6K	Hold	14,886	–	–	﹤0.01%	4309
2016 Q1	$6K	Sell	14,886 -100	-0.7%	-$41	﹤0.01%	4207
2015 Q4	$6K	Buy	14,986 +100	+0.7%	+$47	﹤0.01%	4317
2015 Q3	$9K	Buy	+14,886	New	+$7.63K	﹤0.01%	4354

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Bank of New York Mellon's PVCT Position: Q4 2016 in Review

Bank of New York Mellon sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 14,886 shares — an estimated $1K sold.

Bank of New York Mellon first reported a position in PVCT in Q3 2015 and held it in 5 quarters. The position peaked at $9K in Q3 2015. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Bank of New York Mellon reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Bank of New York Mellon sold 14,886 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $1K.
Bank of New York Mellon first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q3 2015 and held it in 5 quarters.
Bank of New York Mellon's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $9K in Q3 2015.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.